Agios Pharmaceuticals Target of Unusually High Options Trading (AGIO)

Share on StockTwits

Agios Pharmaceuticals Inc (NASDAQ:AGIO) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 3,020 call options on the stock. This is an increase of approximately 3,079% compared to the typical volume of 95 call options.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday. SunTrust Banks reaffirmed a “buy” rating and set a $123.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Wednesday. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday, June 4th. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $97.90.

NASDAQ AGIO opened at $83.82 on Thursday. The company has a market cap of $4.68 billion, a PE ratio of -12.42 and a beta of 1.77. Agios Pharmaceuticals has a 1-year low of $51.62 and a 1-year high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.62) by $0.43. The company had revenue of $40.40 million during the quarter, compared to analyst estimates of $12.47 million. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The company’s revenue was up 257.5% on a year-over-year basis. During the same quarter last year, the business posted ($1.78) earnings per share. equities research analysts forecast that Agios Pharmaceuticals will post -6.01 EPS for the current year.

In related news, Director Kaye I. Foster-Cheek sold 9,000 shares of the stock in a transaction dated Thursday, June 14th. The shares were sold at an average price of $93.55, for a total value of $841,950.00. Following the completion of the transaction, the director now owns 11,200 shares of the company’s stock, valued at $1,047,760. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Bowden sold 1,700 shares of the stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $80.03, for a total transaction of $136,051.00. Following the completion of the transaction, the insider now directly owns 1,224 shares of the company’s stock, valued at approximately $97,956.72. The disclosure for this sale can be found here. Insiders sold 25,122 shares of company stock valued at $2,204,729 in the last three months. Company insiders own 3.02% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Lord Abbett & CO. LLC grew its stake in shares of Agios Pharmaceuticals by 175.8% during the first quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock valued at $85,407,000 after purchasing an additional 665,684 shares during the last quarter. Baillie Gifford & Co. bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $47,607,000. BlackRock Inc. grew its stake in shares of Agios Pharmaceuticals by 14.0% during the first quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock valued at $262,192,000 after purchasing an additional 393,336 shares during the last quarter. Woodford Investment Management Ltd bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $32,849,000. Finally, Wells Fargo & Company MN grew its stake in shares of Agios Pharmaceuticals by 459.8% during the second quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock valued at $34,315,000 after purchasing an additional 334,617 shares during the last quarter. 93.58% of the stock is owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: Investing in Dividend Stocks

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply